Profile for Japan Patent: 2017200942

US Patent Family Members and Approved Drugs for Japan Patent: 2017200942

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
9,675,559	Jan 10, 2033	Eton	ALKINDI SPRINKLE	hydrocortisone
9,717,740	Nov 19, 2032	Eton	ALKINDI SPRINKLE	hydrocortisone

Key insights for pharmaceutical patentability - Japan patent JP2017200942

Last updated: April 25, 2026

What does JP2017200942 cover, and how broad are its claims in Japan?

JP2017200942 is a Japan patent publication (published as a JP publication in 2017) whose claim scope cannot be analyzed to a reliable, decision-grade standard from the information provided in this thread alone. No text of the claims, claim numbering, priority data, applicant/assignee, or IPC/CPC classification for JP2017200942 is present here. Under the constraints, an accurate scope-and-claims review and a defensible Japan-focused patent landscape cannot be produced without the underlying patent document content.

What is the claim scope of JP2017200942?

A claim-scope analysis requires, at minimum, the exact claim set (including independent claims, dependent claims, claim dependencies, functional limitations, ranges, definitions, and any Markush language). Without the claim text and numbering for JP2017200942, any attempt to describe breadth, key limitations, or potential design-around routes would be non-factual.

What is the patent landscape around JP2017200942 in Japan?

A patent landscape requires verifiable inputs such as:

• the publication number and family members (WO/EP/US equivalents, continuations, divisionals),
• status in Japan (granted or pending, lapse, opposition status if applicable),
• citation trail (X/Y citations and related patent families),
• claim overlap with same MoA or same target class (including nearest prior art),
• enforcement-relevant details (scope of claims as granted, claim amendments).

None of these are available in the prompt, and JP2017200942 alone does not supply the underlying family and claim data necessary to map freedom-to-operate risk, potential blockers, or likely landscape clusters.

How should investors and R&D teams treat JP2017200942 until claim text is reviewed?

No decision-grade conclusion can be provided without the claim set. Claim scope drives:

• whether the patent protects the active ingredient, the salt/crystal form, the formulation, the dosing regimen, or the method of treatment,
• whether claim language is composition-based or outcome-based,
• whether there are narrow ranges or broad functional language,
• whether there are enforceable dependents that still capture common manufacturing or clinical regimens.

Key Takeaways

• JP2017200942 cannot be mapped to actionable claim scope or a Japan patent landscape without the underlying patent document content (claims, bibliographic data, and family/citation records).
• Any “breadth,” “scope,” “design-around,” or “risk” statements would be unsupported by the provided materials.

FAQs

1. Is JP2017200942 the same as the first-filed application or a later publication?
   Cannot be determined from the information provided here.

2. Does JP2017200942 protect a compound, a formulation, or a method of treatment?
   Cannot be determined without the claim text.

3. Are there granted claims in Japan or is it still pending?
   Cannot be determined without Japan status data for JP2017200942.

4. What other jurisdictions have the same family as JP2017200942?
   Cannot be determined without family linkage records.

5. What competitors’ patents are most likely to overlap with JP2017200942?
   Cannot be determined without the claims and the citation trail.

References

[1] No cited sources were provided in the prompt or extractable from it.